There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
Ixabepilone is an epothilone analogue that shows cytotoxic potency against tumor cell lines with IC50 values ranging from 1.4 to 34.5 nM. The in vitro IC90 values of ixabepilone in HCT116, HCT/VM46, A2780S, and A2780Tax cells were 7.3, 16, 6.9 and 12 nM, respectively. Ixabepilone potently induced tubulin polymerization with an EC0.01 value of 3.5 μM. Eight-hour exposure of 7.5 nM ixabepilone almost completely blocked HCT116 cells in mitosis[1]. Ixabepilone inhibited cell viability in triple negative breast cancer cell lines with the IC50 values of 10 nM for MDA-MB-231 cells and 8 nM for SUM159 cells. After 72-hour incubation with 5 nM ixabepilone, the mammosphere formation in MDA-MB-231 and SUM159 cells were 0.21% and 0.30%, respectively. In immunocompromised nude rats implanted with Pat-7 tumor, i.v. administration of ixabepilone (3 mg/kg per injection) on a schedule of every 8 days × 2 elicited more than 5 log cell kill, and 4 of 6 cures. In A2780Tax human ovarian carcinoma xenograft, Iiabepilone (6.3 mg/kg per injection) on a schedule of every 2 days × 5 produced 2.5 log cell kill. In a paclitaxel-sensitive tumor model implanted with LS174T human colon carcinoma, ixabepilone (16 mg/kg per injection) administrated every 4 days × 3 yielded 2.3 log cell kill[2].
作用机制
The cellular cytotoxic activities of ixabepilone are linked to the induction of tubulin polymerization and the blockage of cell cycle progression in cancer cells[1].
Ixabepilone/伊沙匹隆 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Docetaxel-resistant MDA-MB-231 cells (TXT)
290 nM
48 hours
Evaluate the effect of Ixabepilone on resistant cell viability, results showed Ixabepilone reduced cell viability to 34.2 ± 3.5% of control.
Pharmacol Rep. 2022 Oct;74(5):998-1010.
MDA-MB-231 parental cells (231C)
22 nM
48 hours
Evaluate the effect of Ixabepilone on cell viability, results showed Ixabepilone significantly reduced cell viability to 29.2 ± 2.0% of control.
Pharmacol Rep. 2022 Oct;74(5):998-1010.
SUM159
5 nM
72 hours
To evaluate the effect of Ixabepilone on cell viability. Results showed that Ixabepilone significantly reduced cell viability in a dose-dependent manner in SUM159 cells (IC50 = 8 ± 2 nM).
Breast Cancer Res. 2016 Jan 12;18(1):6.
MDA-MB-231
5 nM
72 hours
To evaluate the effect of Ixabepilone on cell viability. Results showed that Ixabepilone significantly reduced cell viability in a dose-dependent manner in MDA-MB-231 cells (IC50 = 10 ± 3 nM).
Breast Cancer Res. 2016 Jan 12;18(1):6.
HOVTAX2 cells
10 nM
72 hours
Evaluate the antitumor synergy of ixabepilone combined with sunitinib, results showed significant increase in apoptosis
Gynecol Oncol. 2012 Mar;124(3):589-97.
Human lung cancer cell lines
2.3-19 nM (IC50)
72 hours
Evaluate the cytotoxicity of Ixabepilone against various lung cancer cell lines, showing significant antitumor activity in most cell lines.
Ther Adv Med Oncol. 2011 Jan;3(1):11-25.
Human colon cancer cell lines
4.7-42 nM (IC50)
72 hours
Evaluate the cytotoxicity of Ixabepilone against various colon cancer cell lines, showing significant antitumor activity in most cell lines.
Ther Adv Med Oncol. 2011 Jan;3(1):11-25.
Human breast cancer cell lines
1.4-45 nM (IC50)
72 hours
Evaluate the cytotoxicity of Ixabepilone against various breast cancer cell lines, showing significant antitumor activity in most cell lines.
Ther Adv Med Oncol. 2011 Jan;3(1):11-25.
Ixabepilone/伊沙匹隆 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
SCID/Beige mice
MDA-MB-231 and SUM159 xenograft models
Intraperitoneal injection
10 mg/kg
Weekly
To evaluate the effect of Ixabepilone on xenograft tumor growth. Results showed that Ixabepilone monotherapy significantly prolonged tumor doubling time (TDT = 25 ± 8 days) in SUM159 xenografts, but the effect was not significant in MDA-MB-231 xenografts.
Breast Cancer Res. 2016 Jan 12;18(1):6.
Nu/nu mice or Beige SCID mice
Human xenograft models (including NSCLC, breast cancer, and colon cancer)
Intravenous
6-13 mg/kg (intravenous)
Every 4 days for three doses
Evaluate the antitumor activity of Ixabepilone alone or in combination with other anticancer agents, showing significant antitumor effects in various xenograft models, including tumor growth delay and partial or complete regression.
搜索
HazMat Fee +
